Comparative Pharmacology
Head-to-head clinical analysis: THIORIDAZINE HYDROCHLORIDE versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIORIDAZINE HYDROCHLORIDE versus THORAZINE.
THIORIDAZINE HYDROCHLORIDE vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a typical antipsychotic of the phenothiazine class. It blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also has significant anticholinergic and alpha-adrenergic blocking activity. It exhibits a high affinity for D2, 5-HT2A, and alpha1-adrenergic receptors.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
Adults: Initial 50-100 mg orally three times daily, gradually increasing to maximum 800 mg/day in divided doses. Usual maintenance: 200-800 mg/day.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
24-36 hours for the parent drug; extended in hepatic impairment and elderly; steady-state reached in 4-7 days.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Primarily hepatic metabolism with <1% excreted unchanged in urine; metabolites are excreted renally (approximately 30% of dose as metabolites) and fecally (approximately 20-30% via bile).
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic